1-Bioglutide / NA931
Also known as NA-931, Bioglutide
NA-931 is an investigational compound from Biomed Industries described as a quadruple agonist of the IGF-1, GLP-1, GIP, and glucagon receptors. It has been tested in a registered phase 2 obesity trial.
Clinical-stage research
Size
2 options- Catalog no.
- NVG5
- Specification
- 5mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
NA-931, also called Bioglutide, is being developed by Biomed Industries. The developer and the trial registry describe it as a single agent that activates four receptors involved in metabolism: the IGF-1, GLP-1, GIP, and glucagon receptors. Public descriptions differ on whether it is a peptide or a small molecule, and its structure has not been published in the peer-reviewed literature. A randomized, placebo-controlled phase 2 trial in adults with obesity or overweight (NCT06564753) was completed in 2025. Results have been described in company announcements and conference presentations, but no paper is indexed on PubMed.
Class: Investigational multi-receptor agonist (IGF-1, GLP-1, GIP, and glucagon receptors)
Mechanism of action
How the compound acts, as described in the literature.
According to the developer and the trial registry, NA-931 is intended to act at the GLP-1, GIP, glucagon, and IGF-1 receptors. Receptor binding and potency data have not been published in peer-reviewed form.
GLP-1 and GIP receptor activation are established incretin mechanisms: glucose-dependent insulin secretion and reduced food intake through central appetite pathways.
Glucagon receptor activation is associated with increased hepatic fat oxidation and energy expenditure in studies of other multi-receptor agonists.
IGF-1 receptor activity is unusual among weight-management candidates. The developer links it to lean-mass preservation, which has not been independently evaluated.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
No indexed studies are listed for this product yet.
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
NA-931 is investigational, and no peer-reviewed study of it is indexed on PubMed, so its structure, receptor pharmacology, efficacy, and safety cannot be independently assessed. Reported phase 2 results come from the developer's announcements and conference presentations. The effects of sustained IGF-1 receptor activation in this setting have not been evaluated in published studies.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| NVG5 | 1-Bioglutide / NA931 | 5mg*10vials | 10 |
| NVG10 | 1-Bioglutide / NA931 | 10ml*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.